ABOUT US

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B.

Management Team

Our management team has broad expertise across scientific and business operations, inventing compounds and advancing product candidates through clinical development.

Vipin K. Garg, Ph.D.

Vipin K. Garg, Ph.D.

President and Chief Executive Officer

Scot Roberts, Ph.D.

Scot Roberts, Ph.D.

Chief Scientific Officer

Richard Eisenstadt

Richard Eisenstadt

Chief Financial Officer

M. Scott Harris, M.D.

M. Scott Harris, M.D.

Chief Medical Officer

Bertrand Georges, Ph.D.

Bertrand Georges, Ph.D.

Chief Technology Officer

José Ochoa

José Ochoa

Chief Business Officer

Board of Directors

Wayne Pisano

Wayne Pisano

Director

John M. Gill

John M. Gill

Director

Vipin K. Garg, Ph.D.

Vipin K. Garg, Ph.D.

President and Chief Executive Officer

Partnerships

We believe strategic partnerships break barriers to innovation and we continuously evaluate partnership opportunities. Contact Jose Ochoa, Chief Business Officer, for partnership inquiries.

For partnership opportunities contact:

Jose Ochoa
Chief Business Officer
jochoa@altimmune.com